BeaconEquity.com: CTIC' total net operating expenses for fourth-quarter of 2009 are $26.2M

BeaconEquity.com announces an investment report featuring Cell Therapeutics Inc. (Nasdaq:CTIC). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision. 

The full report is available at: http://www.beaconequity.com/i/CTIC

Get our alerts BEFORE the rest of the market.  Follow us on Twitter: https://twitter.com/BeaconEquity

Cell Therapeutics Inc. (CTIC) develops, acquires and commercializes treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. Its research, development, acquisition and in-licensing activities concentrate on identifying and developing less toxic ways to treat cancer.  

Message Board Search for CTIC: http://www.boardcentral.com/boards/CTIC

In the report, the analyst notes:

"For the quarter ended December 31, 2009, total net operating expenses were approximately $26.2 million, compared to $11.2 million for the same period in 2008. The increase in total net operating expenses was mainly a result of a non-cash equity based compensation expense of $11.7 million for the quarter ended December 31, 2009, and a $9.4 million gain on the sale of Zevalin to a 50/50 owned joint venture with Spectrum that was recognized in the quarter ended December 31, 2008.

"No less than seven class action lawsuits have been filed by various law firms against CTIC and certain officers for violations of federal securities laws in connection to their public statements affecting stock purchased between May 5, 2009, and February 8, 2010."